Urinary Melatonin-sulfate/cortisol Ratio and the Presence of Prostate Cancer: A Case-control Study

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jul 9

PMID 27387675

Citations 27

Authors

Shu-Yu Tai

Shu-Pin Huang

Bo-Ying Bao

Ming-Tsang Wu

Affiliations

Soon will be listed here.

Abstract

The circadian-related hormones, melatonin and cortisol, have oncostatic and immunosuppressive properties. This study examined the relationship between these two biomarkers and the presence of prostate cancer. We measured their major metabolites in urine collected from 120 newly diagnosed prostate cancer patients and 240 age-matched controls from January 2011 to April 2014. Compared with patients with lower urinary melatonin-sulfate or melatonin-sulfate/cortisol (MT/C) ratio levels, those with above-median levels were significantly less likely to have prostate cancer (adjusted OR (aOR) = 0.59, 95% CI = 0.35-0.99; aOR = 0.46, 95% CI: 0.27-0.77) or advanced stage prostate cancer (aOR = 0.49, 95% CI = 0.26-0.89; aOR = 0.33, 95% CI = 0.17-0.62). The combined effect of both low MT/C ratios and PSA levels exceeding 10 ng/ml was an 8.82-fold greater likelihood of prostate cancer and a 32.06-fold greater likelihood of advanced stage prostate cancer, compared to those with both high MT/C ratios and PSA levels less than 10 ng/ml. In conclusion, patients with high melatonin-sulfate levels or a high MT/C ratio were less likely to have prostate cancer or advanced stage prostate. Besides, a finding of a low MT/C ratio combined with a PSA level exceeding 10 ng/ml showed the greatest potential in detecting prostate cancer and advanced stage prostate cancer.

Citing Articles

Night shift work and prostate cancer: a large cohort study from UK Biobank and Mendelian randomisation study.

Yang G, Yang Y, Lv K, Wu Y, Song T, Yuan Q BMJ Open. 2024; 14(12):e084401.

PMID: 39725442 PMC: 11683915. DOI: 10.1136/bmjopen-2024-084401.

Circadian rhythm disruption and endocrine-related tumors.

Savvidis C, Kallistrou E, Kouroglou E, Dionysopoulou S, Gavriiloglou G, Ragia D World J Clin Oncol. 2024; 15(7):818-834.

PMID: 39071458 PMC: 11271730. DOI: 10.5306/wjco.v15.i7.818.

Melatonin Derivative-Conjugated Formulations of Pd(II) and Pt(II) Thiazoline Complexes on Mesoporous Silica to Enhance Cytotoxicity and Apoptosis against HeLa Cells.

Estirado S, Diaz-Garcia D, Fernandez-Delgado E, Vinuelas-Zahinos E, Gomez-Ruiz S, Prashar S Pharmaceutics. 2024; 16(1).

PMID: 38258103 PMC: 10821514. DOI: 10.3390/pharmaceutics16010092.

Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application.

Megerian M, Kim J, Badreddine J, Hong S, Ponsky L, Shin J Aging Dis. 2023; 14(3):840-857.

PMID: 37191417 PMC: 10187692. DOI: 10.14336/AD.2022.1010.

Circadian Rhythm Disruption as a Contributor to Racial Disparities in Prostate Cancer.

Dasari S, Archer M, Mohamed N, Tewari A, Figueiro M, Kyprianou N Cancers (Basel). 2022; 14(20).

PMID: 36291899 PMC: 9600368. DOI: 10.3390/cancers14205116.

References

Bejarano I, Espino J, Barriga C, Reiter R, Pariente J, Rodriguez A . Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects. Basic Clin Pharmacol Toxicol. 2010; 108(1):14-20. DOI: 10.1111/j.1742-7843.2010.00619.x. View

Moussa A, Kattan M, Berglund R, Yu C, Fareed K, Stephen Jones J . A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int. 2009; 105(3):352-8. DOI: 10.1111/j.1464-410X.2009.08778.x. View

Brown S, Hankinson S, Eliassen A, Reeves K, Qian J, Arcaro K . Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II. Am J Epidemiol. 2015; 181(3):155-62. PMC: 4312424. DOI: 10.1093/aje/kwu261. View

Tekbas O, Ogur R, Korkmaz A, Kilic A, Reiter R . Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J Pineal Res. 2008; 44(2):222-6. DOI: 10.1111/j.1600-079X.2007.00516.x. View

Stachon A . [Significance of the PSA-concentration for the detection of prostate cancer]. Pathologe. 2005; 26(6):469-72. DOI: 10.1007/s00292-005-0788-8. View

Sigurdardottir L, Markt S, Rider J, Haneuse S, Fall K, Schernhammer E . Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2014; 67(2):191-4. PMC: 4318783. DOI: 10.1016/j.eururo.2014.07.008. View

DeSantis A, DiezRoux A, Hajat A, Aiello A, Golden S, Jenny N . Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology. 2011; 37(7):1009-18. PMC: 3358540. DOI: 10.1016/j.psyneuen.2011.11.009. View

Touitou Y, Sulon J, Bogdan A, TOUITOU C, Reinberg A, Beck H . Adrenal circadian system in young and elderly human subjects: a comparative study. J Endocrinol. 1982; 93(2):201-10. DOI: 10.1677/joe.0.0930201. View

Reiter R, Gultekin F, Manchester L, Tan D . Light pollution, melatonin suppression and cancer growth. J Pineal Res. 2006; 40(4):357-8. DOI: 10.1111/j.1600-079X.2006.00325.x. View

10.

Jung-Hynes B, Huang W, Reiter R, Ahmad N . Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010; 49(1):60-8. PMC: 3158680. DOI: 10.1111/j.1600-079X.2010.00767.x. View

11.

Panzer A, Lottering M, Bianchi P, Glencross D, Stark J, Seegers J . Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett. 1998; 122(1-2):17-23. DOI: 10.1016/s0304-3835(97)00360-1. View

12.

Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler K, Fluchter S . Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta. 1992; 209(3):153-67. DOI: 10.1016/0009-8981(92)90164-l. View

13.

Carrillo-Vico A, Guerrero J, Lardone P, Reiter R . A review of the multiple actions of melatonin on the immune system. Endocrine. 2005; 27(2):189-200. DOI: 10.1385/ENDO:27:2:189. View

14.

Pirozhok I, Meye A, Hakenberg O, Fuessel S, Wirth M . Serotonin and melatonin do not play a prominent role in the growth of prostate cancer cell lines. Urol Int. 2010; 84(4):452-60. DOI: 10.1159/000296296. View

15.

Schernhammer E, Hankinson S . Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009; 18(1):74-9. PMC: 3036562. DOI: 10.1158/1055-9965.EPI-08-0637. View

16.

Mitin T, Chen M, Zhang Y, Moran B, Dosoretz D, Katin M . Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol. 2011; 186(6):2233-7. DOI: 10.1016/j.juro.2011.07.072. View

17.

Nagata C, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H . Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. Cancer Epidemiol Biomarkers Prev. 2008; 17(6):1418-23. DOI: 10.1158/1055-9965.EPI-07-0656. View

18.

Jung-Hynes B, Schmit T, Reagan-Shaw S, Siddiqui I, Mukhtar H, Ahmad N . Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2010; 50(2):140-9. PMC: 3052633. DOI: 10.1111/j.1600-079X.2010.00823.x. View

19.

Sigurdardottir L, Valdimarsdottir U, Fall K, Rider J, Lockley S, Schernhammer E . Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1002-11. PMC: 3392423. DOI: 10.1158/1055-9965.EPI-12-0116. View

20.

Szczepanik M . Melatonin and its influence on immune system. J Physiol Pharmacol. 2008; 58 Suppl 6:115-24. View